FDA Approves Topical Ruxolitinib for Nonsegmental Vitiligo FDA Approves Topical Ruxolitinib for Nonsegmental Vitiligo

The topical formulation of the JAK1/JAK2 inhibitor was previously approved for atopic dermatitis.FDA Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Alert Source Type: news